van der Heijde D, et al. - Researchers presented the 4-year imaging outcomes in the RAPID-axial spondyloarthritis (axSpA) study of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), treated with certolizumab pegol (CZP). Rapid decreases in spinal and sacroiliac joints (SIJ) MRI inflammation were maintained to week 204 in patients with CZP-treated axSpA. Overall, low 4-year spinal progression was seen with less progression during years 2-4 than 0-2. Limited progression was demonstrated with radiographic SIJ grading changes.